evogliptin

ApprovedSmall molecule

evogliptin is one of 201 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

200

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Aortic StenosisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Chronic HepatitisActive, not recruiting

Type 2 DiabetesActive, not recruiting

Renal InsufficiencyActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Aortic StenosisPhase 2/Phase 3

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Chronic HepatitisApproved

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Renal InsufficiencyPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

evogliptin

DDong-A ST Co., Ltd.

Approved

3 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Recruiting

Aortic Stenosis

NCT05143177

Clinical

Trials by Indication[1]

Type 2 Diabetes3 trials

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)

Completed·DDong-A ST Co., Ltd.·Phase 4·NCT02974504·207 enrolled

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed·DDong-A ST Co., Ltd.·Phase 3·NCT04356742·198 enrolled

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed·DDong-A ST Co., Ltd.·Phase 3·NCT04170998·283 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes

Completed·DDong-A ST Co., Ltd.·Phase 3·NCT02949193·222 enrolled

A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin

Completed·DDong-A ST Co., Ltd.·Phase 3·NCT02946541·160 enrolled

Clinical Trial2 trials

A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg

Unknown status·DDong-A ST Co., Ltd.·Phase 4·NCT04653779·54 enrolled

A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Unknown status·KKyung Hee University Hospital at Gangdong·Phase 4·NCT04706637·120 enrolled

Renal insufficiency1 trial

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

Completed·SSamsung Medical Center·Phase 2·NCT03667300·209 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases

Completed·DDong-A ST Co., Ltd.·Phase 4·NCT03910361·51 enrolled

8 more indications

Randomized1 trial

Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

Unknown status·—·Phase 4·NCT04521452·218 enrolled

Aortic Stenosis1 trial

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Recruiting·RREDNVIA Co., Ltd.·Phase 2/3·NCT05143177·580 enrolled

Function1 trial

Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT02754219·24 enrolled

Dialysis Patients1 trial

The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT04195919·17 enrolled

Chronic Hepatitis1 trial

Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Unknown status·SSeung Up Kim·Phase 4·NCT05473806·28 enrolled

Metabolism1 trial

Effect of Evogliptin on Bone Metabolism in Human

Unknown status·—·Phase 4·NCT02587975·20 enrolled

Observational Study1 trial

Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

Unknown status·DDong-A ST Co., Ltd.··NCT04326166·1,971 enrolled

Type 2 Diabetes Mellitus1 trial

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

Completed·EEurofarma Laboratorios S.A.·Phase 2·NCT02689362·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for evogliptin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — evogliptin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for evogliptin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dong-A ST Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDong-A ST Co., Ltd.

evogliptin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 2 Diabetes3 trials

Efficacy and Safety2 trials

Clinical Trial2 trials

Renal insufficiency1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Randomized1 trial

Aortic Stenosis1 trial

Function1 trial

Dialysis Patients1 trial

Chronic Hepatitis1 trial

Metabolism1 trial

Observational Study1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News